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Abstract
The immune response of the intermediate host with alveolar echinococcosis was
investigated on mice intraperitoneally infected with Echinococcus multilocularis
protoscoleces. The study was focused on cell-mediated immune response (dependent
on interactions of T lymphocytes and macrophages), which is considered protective
in alveolar echinococcosis. The immune response to E. multilocularis is regulated by
Th1/Th2 cytokines produced by the CD4+ T lymphocyte subpopulation. Metacestode
has been known for its ability to modify immune functions and suppress effective
specific cell response to ensure its survival in host organism. The influence of
immunomodulatory substances – muramyltripeptide (L-MTP-PE), glucan (GI),
glucan with zinc (GIZn), and transfer factor (TF) – applied alone or combined with
anthelmintic albendazole (ABZ) on regulative and effector components of immunity
were tested and at the same time, antiparasitic efficacy of immunomodulators was
evaluated.
Keywords: Echinococcus multilocularis, therapy, muramyltripeptide, glucan, transfer
factor
1. Introduction
The larval stage of Echinococcus multilocularis causes alveolar echinococcosis, the serious
helminthozoonosis with a high mortality in patients with late treatment [1]. The disease is
characterized by an infiltrative, tumor-like growth of the E. multilocularis larval cysts, affecting
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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the liver of intermediate hosts such small mammals or man [2]. The therapy of this disease
represents an important problem. The treatment with available anthelmintics (benzimida‐
zoles, praziquantel a.o.) is long term and relatively little effective. A surgical extirpation of
cysts is not always successful owing to their ability to form metastatic foci in secondarily
infected organs [3, 4]. The available treatment has only parasitostatic effect and is therefore
performed over many years, often through the patient’s life [5]. This brings the risk of adverse
reactions of drugs, among which gastrointestinal disturbances, reversible alopecia, hepatitis,
proteinuria, neurological symptoms are the most frequent [5, 6], apart from a strong terato‐
genic effect [7]. The disadvantage of benzimidazoles consists also in irresponsiveness to
treatment in some patients and recurrence of the disease after intermission of the therapy [8].
There is still no consensus regarding the effective dosage and duration of treatment [9, 10].
Moreover, the immunological status of the host, host susceptibility, and actual stage of
infection influence the results of treatment [11]. The generalized immunosuppression induced
by E. multilocularis may complicate therapy efficacy in alveolar echinococcosis. E. multilocula‐
ris evades the host immune response by mechanisms that protect the parasite or modify the
host immunity to ensure its long-lasting survival in the host organism [12, 13]. Application of
immunomodulatory substances could improve host immune status during E. multilocularis
infection and limit the growth of the parasite. Results of alternative therapeutic strategies with
use of immunomodulatory substances seem to be promissing and might contribute to higher
efficacy of the anti-Echinococcus treatment.
E. multilocularis induces parasite-specific cellular and humoral immune response in inter‐
mediate host [14]. The infection induces strong cellular immune response and production of
all antibody isotypes, which are not effective in killing and elimination of parasites. Cellular
immune response, leading to granulomatous infiltration of peri-parasite tissue, plays the
dominant role in the fight with echinococcus [15]. Cell-mediated immune response depending
on interaction of macrophages and T lymphocytes is regarded as protective against E.
multilocularis infection [16]. On the contrary, E. multilocularis is able to evade host immune
response or modify it to ensure its long-lasting survival in the organism of the intermediate
host [12, 13]. Different activation of T cells subsets (CD4+, CD8+) and the combined Th1 and
Th2 cytokine profile appear crucial for prolonged metacestode growth and survival. Regres‐
sive, as well as progressive course of the disease correlates with stadium-specific granuloma
cell composition and antigen-specific T cell response [17]. An activation of Th1 CD4 T lym‐
phocytes is connected with the control of the infection [18] and a reversion to Th2 response
may contribute to long-lasting manifestation of E. multilocularis infection in humans [12, 19].
The E. multilocularis metacestode can specifically manipulate the balance between Th1 and Th2
response leading to lowered effectiveness of immune response [20]. Macrophages on the
periphery of the periparasitic granuloma can produce proinflammatory cytokines continually
serving as mediators of acute phase of protein secretion and fibrogenesis [14]. Granuloma
generation and fibrosis can restrict larval growth, but also reduces anthelmintic drug transport
to the lesion and thus may be the reason for partial or total ineffectiveness of treatment [20].
Application of immunomodulatory substances could improve the host immune status during
E. multilocularis infection and limit the growth of the parasite. New therapeutic approaches to
alveolar echinococcosis use immunomodulators to overcome patient’s immunosuppression
(caused by E. multilocularis metacestode) that complicates benzimidazole therapy. The
application of cytokine IFN-γ or IL-12 together with benzimidazoles stopped the progression
Current Topics in Echinococcosis160
of disease or limited the metacestode growth [17, 21], suggesting its usefulness in therapy.
However, the use of recombinant cytokines in therapy is technically and financially demand‐
ing. Therefore, new ways to support a secretion of endogenous cytokines in patients are sought.
In our study, we focused on the activity of three immunomodulators (liposomized muramyl‐
tripeptide, glucan with zinc, and transfer factor) in enhancing of the host antiparasite defence
and the efficacy of anthelmintic albendazole treatment in alveolar echinococcosis.
2. Materials and methods
Experiments were performed on pathogen-free BALB/c mice, males, weighing 20–25 g. Mice
were kept under a 12-h light/dark regime at room temperature (21±3°C) and 50–60% relative
humidity on a commercial diet and water. The experimental protocols complied with the
current Slovak ethics law.
Figure 1. Protoscoleces of Echinococcus multilocularis.
2.1. Infection
E. multilocularis metacestode (strain provided by Department of Medical Parasitology, Clinical
Institute of Hygiene and Medical Microbiology, Medical University of Vienna, Austria) was
passaged in our laboratory by intraperitoneal injection of Mongolian jirds Meriones unguicu‐
latus.
Parasite cysts were isolated 4 months post infection (p.i.) and cut into pieces in sterile RPMI
1640 medium (Sigma-Aldrich, Germany) supplemented with antibiotics, 100 U/ml penicillin
and 100 μg/ml streptomycin (Sigma-Aldrich, Germany), and passed through a Cell Dissocia‐
tion Sieve Tissue Grinder Kit using apertures ranging from 380 to 45,7 μm (Sigma-Aldrich,
Germany).
Protoscoleces obtained after the last filtration were maintained in RPMI and counted for an
infective dose.
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2.2. Efficacy of treatment
The antiparasitic efficacy of immunotherapy was evaluated by the cyst development in
infected mice. E. multilocularis cysts were isolated from sacrificed mice and parasite cysts were
weighed and subsequently mean value ± S.D. was determined (n=3 or n=4).
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Figure 2. A – Mice infected with E. multilocularis. B – Cysts of E. multilocularis in the peritoneal cavity of an infected
mouse (4th month after the infection).
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Figure 3. A – The affected liver with E. multilocularis cysts. B – Cysts of E. multilocularis isolated from the peritoneal
cavity of an infected mouse (4th month after the infection).
2.3. T and B lymphocyte proliferation assay
The spleen was aseptically homogenized in phosphate-buffered saline (PBS) (pH 7.2) to obtain
cells. Cell suspension was washed twice with PBS and finally with RPMI 1640 medium (Sigma-
Aldrich, Germany). Erythrocytes were removed by lysis in hypotonic solution (0.85 % NH4Cl)
and lymphocytes were resuspended to a final concentration of 5 x 106 cells /ml in RPMI 1640
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medium. The assay was performed in 96 wells plates (Nunc, Denmark) and cells were
incubated in RPMI 1640 medium (100 μl) containing 10 % bovine fetal serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin. Mitogens Concanavalin A (Con A) (T cells) and
lipopolysaccharide (LPS) (B cells) (Sigma-Aldrich, Germany) were added in a dose 100 μl
(concentration 10 μg/ml) to the cell suspensions and incubated at 37 °C in 5 % CO2 and 85 %
humidity for 72 h. Then 20 μl of 3,4-dimethylthiazolyl 2,5-diphenyltetrazolium bromide
(Sigma-Aldrich, Germany) (0.1 % solution) was added to the cell suspensions and incubated
at 37 °C and 5 % CO2 for 4 h followed by centrifugation at 800 x g for 5 min. Reaction was
terminated with dimethylsulfoxide (Sigma-Aldrich, Germany) (100 μl/cell sample) and read
on ELISA reader (Multiskan Plus, Labsystem, Finland) at 540 and 630 nm. The stimulation
indices (SI) were calculated according to the formula:
SI= E540 – E630 (stimulated cells) / E540 – E630 (unstimulated cells)
Proliferative responses were measured separately for lymphocytes isolated from each mouse
per group.
2.4. Number of CD4+ and CD8+ T cells
Lymphocytes from the spleens and depleted of erythrocytes were resuspended in PBS (pH
7.2) at a final concentration of 1x 106 cells /ml. Monoclonal antibodies rat anti-mouse CD4
fluorescein isothiocyanate-conjugated and rat anti-mouse CD8 phycoerythrin-conjugated
monoclonal antibodies (BD Biosciences PharMingen, Belgium) were used at the concentration
of 0.4 μg/106 cells at 4°C for 30 min. After washing in PBS three times, cells were analyzed by
the FACScan flow cytometer (Becton Dickinson Biosciences, Germany) and CellQuest
software. Cells from each mouse per group were analyzed individually. The final numbers of
both cell populations were calculated as proportion from the total isolated lymphocytes per
spleen/mouse.
2.5. Concentration of IFN-γ and IL-5 in serum
The capture ELISA was employed to determine the concentration of cytokines IFN-γ and IL-5
in serum according to the method [22]. IFN-γ and IL-5 were used as marker cytokines for the
Th1 and Th2 responses, respectively. Cytokine-specific monoclonal antibodies were used, for
IFN-γ detection: pure anti-mouse IFN-γ (R4-6A2) and biotin anti-mouse IFN-γ (XMG1.2); for
IL-5 detection: pure anti-mouse IL-5 (TRFK5) and biotin anti-mouse IL-5 (TRF4) (all BD
Biosciences PharMingen, Belgium). Results were expressed at pg/ml using murine recombi‐
nant IFN-γ and IL-5 (BD Biosciences PharMingen, Belgium) as standards. The detection limit
of the assay for the both cytokines was 40 pg/ml.
2.6. Superoxide anion assay
Production of superoxide anion (O2-) by peritoneal macrophages was detected as superoxide
dismutase (SOD) – reduction of ferricytochrome C with and without stimulation with phorbol
myristate acetate (PMA) [23]. Cells were obtained by peritoneal lavage and after washing in
PBS were diluted at concentration of 1 x 106 cells/ml in RPMI 1640 (Sigma-Aldrich, Germany).
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Cell suspension (1 ml/well) was added to 24-well plate (Falcon, France) and incubated at 37
oC in 5 % CO2 and 85 % humidity for 2 h. Nonadherent cells were removed by washing with
ice-cold Earls Balanced Salt Solution (EBSS) (pH 7.2). The reaction was carried out in 0.3 ml/
well of 160 μM ferricytochrome C (Sigma-Aldrich, Germany) in EBSS. In control, the reaction
was immediately blocked by 300 μg SOD/10 μl in EBSS. The stimulation of cells was induced
by 10 μl of PMA in ethanol. Cells were incubated at 37 oC in 5 % CO2 and 85 % humidity for 2
h. Supernatant from wells was centrifuged at 170 x g for 3 min at 4 oC. The optical density (OD)
of supernatant was measured at 550 nm in a 96-well plate reader (Multiscan Plus, Labsystems,
Finland). Bradford protein microassay was used to determine cell-protein concentration in
each well with standard reagent and bovine serum albumin as the protein standard (BioRad,
UK). The OD was read at 595 nm. The resulting value was used to calculate nmol of O2-
produced according to the formula: nmol O2- = (ODblocked by SOD - ODwithout SOD /6.3) x 100 and
determinated for 1 mg of cell proteins.
2.7. Statistical evaluation
Statistical differences were assessed using Kruskal-Wallis ANOVA and post hoc Tukey’s HSD
test (a value of p<0.05 was considered significant) in the program Statistica 6.0 (Stat Soft, Tulsa,
USA) statistical package.
3. Muramyltripeptide
Muramylpeptides – components of bacterial cellular wall are classified as biological immu‐
nomodulators. Muramylpeptides primarily activate macrophages to a high production of
oxygen radicals and a secretion of inflammatory cytokines, which activate neutrophils, T and
B lymphocytes [24]. Muramyldipeptide (MDP) is the smallest bacterial structure with immu‐
nopotent activity. The positive effect of MDP on the host immune response was also observed
in several parasitic infections [25–27]. Muramyltripeptide phosphatidylethanolamine (MTP-
PE) is a lipofilic derivate of MDP. Liposome-encapsulated MTP-PE has an enhanced effect on
macrophages to secrete pro-inflammatory cytokines, which results in increasing of cytotoxicity
of these cells [28–30].
Affinity of liposomized forms of MTP-PE to the reticuloendotelial system, in particular to
macrophages located in the liver and the spleen [30, 31], could be useful in therapy of alveolar
echinococcosis, by which the parasite cysts primarily develop in the liver. The biological effect
of MTP-PE takes place in Kuppfer cells in the liver (macrophage’s equivalent) [32]. Macro‐
phages activated by liposomized MTP-PE stimulate Th1 subpopulation of lymphocytes and
proinflammatory mediators via cytokine secretion [28, 29, 33, 34]. T lymphocytes therefore
constitute an active component of immune reactions after immunomodulation with mura‐
mylpeptides.
The effect of muramyltripeptide phosphatidylethanolamine incorporated into multilamellar
liposomes (L-MTP-PE) on immune response of intermediate host infected with E. multilocula‐
ris was examined.
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3.1. Experimental design
Experiments were carried out on male BALB/c mice (n=150) weighing 20–25 g. Mice were
randomly divided into five groups as follows:
Group 1 – uninfected and untreated (control)
Group 2 – infected intraperitoneally with 5000 E. multilocularis protoscoleces/mouse on Day 0
and no treatment
Group 3 – E. multilocularis infected (as Group 2) and treated with liposomized muramyltri‐
peptide phosphatidylethanolamine (L-MTP-PE) (Ciba-Geigy, Switzerland) intravenously
(i.v.) twice a week at the dose of 1 mg/kg of body weight (b.w.) starting at weeks 5 and 6 post
infection (p.i.)
Group 4 – E. multilocularis infected (as Group 2) and treated with albendazole (ABZ) (Sigma,
Germany) per os (p.o.) twice a week at the dose of 10 mg/kg of b.w. starting at week 5 up to
week 10 p.i.
Group 5 – E. multilocularis infected (as Group 2) and treated with combination of L-MTP-PE
and ABZ as above.
Samples of blood, spleen, and peritoneal macrophages were obtained at the following weeks:
0 (prior infection), 2, 4, 8, 10, 12, 14, 18, 22, and 26 p.i. from all groups (3 mice per experimen‐
tal day).
4. Results and discussion
In our experiment, the E. multilocularis infection induced an inhibition of the proliferative
activity of T and B lymphocytes almost in the course of the whole experiment (Figures 4, 5).
However, the application of L-MTP-PE to infected mice had a positive stimulatory effect on T
and B lymphocytes, especially in combination of L-MTP-PE+ABZ, where proliferative activity
of lymphocytes was increased for a long time, from week 8 p.i. (2 weeks after the end of the
therapy) till week 14 p.i. (lasted almost 2 months). Muramylpeptides belongs to the polyclonal
activators of B lymphocytes, inducing a high proliferation and production of polyclonal
antibodies. Muramyldipeptide activates B cells particularly during a late phase of their
differentiation because the specific receptors for MDP are expressed on B cell surface at a
definitive stage of their maturation [35].
T lymphocytes play a major role in the control of immune response in intermediate host
organism infected with E. multilocularis [36]. In alveolar echinococcosis CD4+ T cells represent
the main T subpopulation, being abundant in the first phase of the periparasitic granuloma
formation and later these cells are replaced by CD8+ T cells [17]. A long-term stimulation of
CD4+ T cell subpopulation after the immunotherapy could participate in antiparasite defence
(to form the periparasitic granuloma) and increase its efficacy. Both L-MTP-PE alone and
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combination of L-MTP-PE+ABZ increased the presence of CD4+ T cells in the spleen of infected
mice within 6 weeks after the immunotherapy (Figure 6).
Previous experimental studies have manifested that E. multilocularis infection can lead to an
expansion of CD8+ T cell clones [18, 37, 38]. In our study (Figure 7), the CD8+ T cells occurrence
was higher for a short time in mice after therapy with L-MTP-PE than in infected and non‐
treated mice. Combined therapy L-MTP-PE+ABZ induced high values of CD8+ T cells, which
remained increased till the end of the experiment. Splenic suppressive CD8+ T cells in alveolar
Figure 4. Proliferative activity of T lymphocytes in E. multilocularis infected mice after therapy L-MTP-PE+ABZ.
*(p<0.05); **(p<0.01) statistically significant from infected mice.
Figure 5. Proliferative activity of B lymphocytes in E. multilocularis infected mice after therapy L-MTP-PE+ABZ.
*(p<0.05); **(p<0.01) statistically significant from infected mice.
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echinococcosis have a key role in modulation of immunosuppression and ensure the parasite
survival in a host [20, 38]. Results in our experiment do not differentiate between cytotoxic
and suppressor subtypes of CD8+ T cells and which one of them dominates. In alveolar
echinococcosis, the CD8+ T splenocytes consist mostly of T suppressors with a low density of
the CD8 antigen [37]. In our experiment, the immunotherapy suppressed the proliferation of
E. multilocularis cysts and therefore we suppose L-MTP-PE could increase the occurrence of
cytotoxic CD8+ T cells. Immunomodulator L-MTP-PE has also stopped a decrease of the CD4/
Figure 6. Number of splenic CD4 T cells in E. multilocularis infected mice after therapy L-MTP-PE+ABZ. *(p<0.05);
**(p<0.01) statistically significant from infected mice.
Figure 7. Number of splenic CD8 T cells in E. multilocularis infected mice after therapy L-MTP-PE+ABZ. **(p<0.01) stat‐
istically significant from infected mice.
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CD8 ratio and the CD4/CD8 index was stabilized over 2.00. This reflects that CD4+ T lympho‐
cytes were in the majority despite the increased values of CD8+ T lymphocytes. CD4+ T cells
together with macrophages and IFN-γ actively participate in parasite’s destruction [39].
In many parasitic infections, the clinical outcome of the disease is associated with Th1 or Th2
cell activation. E. multilocularis metacestode is able to direct a host immune response to a less
efficient, “tolerant” Th2 profile [20, 40]. In [34, 41] it was found that liposomized immunomo‐
dulators induce a development of splenic Th1 lymphocyte subpopulation. The dominance of
Th1 response is important in defensive reactions of a host infected with E. multilocularis. IFN-
γ is an important activator of macrophages and affects their energetic system [21]. In our study
(Figure 8), the level of IFN-γ peaked after L-MTP-PE+ABZ therapy from weeks 8 to 18 p.i. (i.e.,
almost 3 months), which outlines an important credit of common administration of immuno‐
modulators and anthelmintic drugs for therapy of alveolar echinococcosis. The protective
effect of combined therapy L-MTP-PE+ABZ was the most evident during the time with IFN-
γ stimulation (lasting 3 months after the therapy), manifesting in breaking of parasite’s
development (Figure 11).
Figure 8. Serum IFN-γ in E. multilocularis-infected mice after therapy L-MTP-PE+ABZ. *(p<0.05); **(p<0.01) statistically
significant from infected mice.
Liposomized MTP-PE suppressed the Th2 response, associated with a progressive develop‐
ment of larval cysts in E. multilocularis infection. In our experiment, the Th2 response was
suppressed in mice treated with L-MTP-PE; we recorded almost twofold reduction of IL-5
production (Figure 9) during the whole experiment. We observed a total IL-5 cytokine
suppression in mice treated with combined therapy L-MTP-PE+ABZ. The cytokine IL-5 is
related to eosinophilia, IgE production, and may induce allergic reactions of the disease [19,
42, 43]. The therapeutic regime of L-MTP-PE in our experiment was timed on the first stage of
the E. multilocularis infection, which is characterized by secretion of Th1 cytokines IL-2 and
IFN-γ [20]. In this early phase of the infection, Th2 response has not been activated in sub‐
stantial extent. Th2 response decreases a synthesis of proinflammatory Th1 cytokine IFN-γ by
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antagonistic IL-10 secretion and by inhibited IL-12 production in macrophages [44, 45].
Therefore, there is a higher possibility of an activation of protective Th1 response by immu‐
nomodulator before the stage when an expansive metacestode growth takes place (approx.
from week 8 p.i.).
Figure 9. Serum IL-5 in E. multilocularis infected mice after therapy L-MTP-PE+ABZ. *(p<0.05); **(p<0.01) statistically
significant from infected mice.
Macrophages participate in the destruction of the parasite through synthesis of O2- and other
free radicals and, together with T cells, control the parasite development [39]. In our experi‐
ment (Figure 10), therapy L-MTP-PE stimulated O2- generation in infected mice from weeks 8
to 12 p.i. (i.e. for 1 month). The combination of L-MTP-PE+ABZ significantly increased the
superoxide production from weeks 8 to 18 p.i. (almost for 3 months).
Figure 10. Macrophage’s activity in E. multilocularis infected mice after therapy L-MTP-PE+ABZ. *(p<0.05); **(p<0.01)
statistically significant from infected mice.
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It documents a long-term and strong activation of macrophage’s metabolism accompanied
with a huge release of other biologically effective substances. In parallel, the proliferative
activity of B cells was also increased, which could be related to macrophages’ stimulation
induced by B cell secrets [46]. Positive effect of L-MTP-PE on macrophages had been confirmed
in immunosuppressed mice [25], in which the immunomodulator induced a macrophages
restoration. An induction of cytotoxicity of liver macrophages against tumor cells after
stimulation with L-MTP-PE was observed [28]. In addition, an increased tumoricidal activity
of Kupffer cells in mice after application of L-MTP-PE was recorded [47]. Their results were
later corroborated in the work [48], which described an activation of Kupffer cells with an
increased production of superoxide anion and subsequent reduction of micrometastases in
rats after MTP-PE therapy.
Macrophages’ stimulation in situ is selectively influenced by a way of application of liposom‐
ized immunomodulator, and also by other biological substances. In [49], L-MTP-PE adminis‐
tered alone stimulated peritoneal macrophages with less effect than after coincubation of
macrophages with L-MTP-PE and IFN-γ together, which doubled their cytotoxic activity. The
synergetic and potentiating effect of IFN-γ in the immunomodulatory acting was also verified
on macrophages infected with Listeria monocytogenes [50], in mice infected with Klebsiella
pneumoniae [34]. These data confirmed an important role of T cells in immune activation of the
host organism after the immunomodulator administration.
Potentiation of effector components of the immunity after the immunomodulation and
anthelmintic therapy of E. multilocularis infected mice in our experiment resulted in a restric‐
tion of the parasite development and reduced larval cysts in a host organism (Figure 11). The
immunomodulator L-MTP-PE administered alone slowed down E. multilocularis proliferation
till week 14 p.i. and combination of L-MTP-PE+ABZ reduced the parasite development till
week 22 p.i. (i.e., 3 months after the end of the experiment). A similar synergism of liposomized
MDP and antiparasitic drug Glucantime was observed in visceral leishmaniasis [51].
Figure 11. Cyst’s weight in E. multilocularis infected mice after therapy L-MTP-PE+ABZ. *(p<0.05); **(p<0.01) statistical‐
ly significant from infected mice.
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In conclusion, our results show the possibility to increase antiparasitic efficacy of ABZ in E.
multilocularis infection with L-MTP-PE, which properly stimulates the host immune response.
Combined therapy L-MTP-PE+ABZ positively increased CD4+ T cells numbers and cytokine
production that regulate the host immune response. The immunotherapy suppressed the Th2
response and vice versa activated the Th1 response with a restrictive impact on the parasite
development. The immunomodulator L-MTP-PE stimulated macrophages’ metabolism to
produce reactive oxygen substances and together with IFN-γ increased an antiparasitic
efficacy of albendazole.
5. Glucan and zinc
Glucans are β-(1,3)-D polymers of glucose occuring naturally as the basic component of the
cell walls of bacteria, fungi, and yeast [52–54]. Glucans activate mainly nonspecific stimulation
of the immune system [22], particularly proliferation and functional activity of phagocytic cells
(macrophages, NK cells) as the part of innate immunity [55, 56], but also have an influence on
specific immunity – increase of the T-lymphocyte activity and production of circulating
antibodies [57–59]. The immunostimulative effect of glucan could be increased by its combi‐
nation with the other components – immunoglobulin G, zinc, or vitamin C [60, 61]. Zinc
interacts with cytokines and proteases and indirectly influences the immune system [62]. Its
immunostimulative effect on T lymphocytes, macrophages has been known [63–65] and so
zinc could potentiate the immunostimulative effect of the glucan during therapy of alveolar
echinococcosis. Also living Echinococcus needs zinc for growth and its reproduction [66]. An
obvious association between serum zinc concentration and disease severity in patients with
alveolar echinococcosis was confirmed in [67]. Decreased zinc concentration in progressive
cases may be a consequence of enhanced immune activation and also consumption of zinc by
the growing parasite. Zinc deficiency in the host may thus contribute to the observed immu‐
nosupression in alveolar echinococcosis.
The role of glucan immunomodulator (GI, soluble β-(1,3)-D glucan) and/or glucan immuno‐
modulator supplemented with zinc (GIZn) in stimulation of a host defence mechanism against
E. multilocularis infection and the immunomodulator’s effect on albendazole antiparasitic
efficacy was observed.
5.1. Experimental design
Experiments were carried out on male BALB/c mice (n=220) weighing 20–25 g. Mice were
divided randomly into five groups as folows:
Group 1 – uninfected and untreated (control)
Group 2 – infected intraperitoneally with 5000 E. multilocularis protoscoleces/mouse on Day 0
and no treatment
Immunotherapy Can Enhance Anthelmintic Efficacy in Alveolar Echinococcosis
http://dx.doi.org/10.5772/59732
171
Group 3 – E. multilocularis infected (as Group 2) and treated with albendazole (ABZ) (Sigma,
Germany) per os (p.o.) twice a week at the dose of 10 mg/kg of b.w. starting at week 5 up to
week 10 p.i.
Group 4 – E. multilocularis infected (as Group 2) and treated with ABZ (as above) and glucan
immunomodulator (GI) (Dimenzia, Slovak Republic) twice a week at the dose of 5 mg/kg b.w.
at weeks 5 and 6 p.i.
Group 5 – E. multilocularis infected (as Group 2) and treated with ABZ (as above) with glucan
supplied with zinc (GIZn) (Mevac, Slovak Republic) twice a week at the dose of 5 mg/kg b.w.
at weeks 5 and 6 p.i.
Samples of blood, spleen, and peritoneal macrophages were obtained at the following weeks:
0 (prior infection), 2, 4, 6, 8, 10, 12, 14, 18, 22, and 26 p.i. from all groups (four mice per
experimental day).
6. Results and discussion
The Echinococcus multilocularis infection in our experiment inhibited the proliferative activity
of T and B lymphocytes within 26 weeks of the experiment (Figures 12, 13), with the minimum
at weeks 2 and 4 p.i., that is, in the early stage of infection, during the time important for the
parasite establishment. These data correlate to results of other authors [17, 68] and it could be
caused by immunosuppressive factors released by protoscoleces of E. multilocularis. The T cell
proliferation (Figure 12) was stimulated in infected mice with GI+ABZ therapy from week 6
to 10 p.i., at the beginning of the progressive larval growth in infected mice without treatment.
The GI stimulatory activity was prolonged for 4 weeks by zinc supplementation in GIZn
immunomodulator. This confirms an important role for zinc in immune response, specifically
lymphocyte proliferation induced by mitogens. T-cell division, maturation, and differentiation
require an adequate zinc content [65, 69]. Even after ABZ therapy, the proliferative activity of
T lymphocytes was increased during drug’s administration, from week 6 to 12 p.i., similarly
to another works [68, 70]. The modulatory effect of albendazole could be derived from the fact
that a drug induces direct morphological and structural changes of parasite cysts walls and
protoscoleces [71], which lead to the revealing of normally unexposed structural antigens,
which are presented to T lymphocytes. It results in inducing a Th2 response (chronic antigen
stimulation) or a Th1 response (small parasitic lesions or reduced antigen output/recognition)
[72]. The positive synergistic effect of anthelmintic ABZ and immunomodultor GIZn resulted
in a prolonged increased T cell proliferation for 8 weeks after the end of drug’s administration.
Immunomodulators GI and GIZn did not induce such stimulative effect on B cell proliferation
(Figure 13); they restored a suppressed proliferative activity of B cells only for a short time.
The similar restoring effect of glucan was observed in other parasitic infections with Ascaris
suum or Toxocara canis [60, 73–75]. The weaker influence of GIZn on B cells could be explained
by the fact that severe zinc deficiency impairment of B cell function is rarely seen [76, 77] and
also the humoral response of patients with progressive alveolar echinococcosis was not
affected by zinc deficiency [67]. Both combined therapies GI+ABZ and GIZn+ABZ reinforced
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a stimulatory activity of ABZ on B cell subpopulation from week 6 to 14 p.i., during the
intensive cyst’s growth in infected mice without treatment. The functional activity of T
lymphocytes in cellular response to E. multilocularis infection is associated with two subpo‐
pulations of CD4+ and CD8+ T cells. A time-dependent supression of T cell proliferative
response was observed in [78], and authors also recorded in vitro CD4 T cells’ decrease and
vice versa CD8 T cells’ increase in splenocytes after activation with E. multilocularis protosco‐
leces.
Figure 12. Proliferative activity of T lymphocytes in E. multilocularis infected mice after immunotherapy with GI or
GIZn. *(p<0.05); **(p<0.01) statistically significant from infected mice.
Figure 13. Proliferative activity of B lymphocytes in E. multilocularis infected mice after immunotherapy with GI or
GIZn. *(p<0.05) statistically significant from infected mice.
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Figure 14. Number of splenic CD4 T cells in E. multilocularis infected mice after immunotherapy with GI or GIZn.
*(p<0.05); **(p<0.01) statistically significant from infected mice.
Figure 15. Serum IFN-γ in E. multilocularis infected mice after immunotherapy with GI or GIZn. *(p<0.05); **(p<0.01)
statistically significant from infected mice.
CD4 T cells represent the main T subpopulation in the first phase of alveolar echinococcosis
in granuloma formation around the parasite [17, 79]. In our experiment (Figure 14), the
presence of CD4 T cells was stimulated from weeks 6 to 8 p.i. in the spleen of mice infected
and treated with GI+ABZ. Supplementation of glucan with zinc could contributed to prolong
an increase in the CD4 T cell subpopulation in mice treated with GIZn+ABZ from week 6 to
14 p.i. It has been known that zinc deficiency reduces the production of IL-4 cytokine acting
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as a growth factor for helper CD4 T cells [80]. The long-term stimulation of CD4 T cells after
GIZn+ABZ therapy could increase antiparasite defence. Periparasitic granuloma in regressive
alveolar echinococosis is composed of great numbers of CD4 T lymphocytes, macrophages,
and myofibroblasts [81]. In patients with progressive disease, the CD8 T lymphocytes are
dominant [82]. In our experiment, E. multilocularis infection did not induce serious changes in
T cells. The CD8 T lymphocytes were not influenced by immunotherapy, except for a light
growth in the CD8 T cell numbers at weeks 12 and 14 p.i. in mice infected and treated with
GIZn+ABZ, which could be helpful in the development of immunosuppression of the host.
The Th1 and Th2 cytokine balance regulates the immune response to E. multilocularis [19]. The
possible effect of the immunotherapy on the Th1/Th2 balance was evaluated according to
serum levels of cytokines IFN-γ and IL-5. GIZn+ABZ therapy stimulated the level of serum
IFN-γ with the strongest and longest effect in mice with E. multilocularis infection from week
8 to 22 p.i. (Figure 15). This result documents the positive effect of GIZn immunomodulator
on preferential Th1 stimulation. Immunomodulators GI and GIZn decreased the serum level
of IL-5 from week 6 p.i. (Figure 16). The strong Th2 downregulative effect of both glucan
immunomodultors stopped the rise of IL-5 (recorded in mice infected and without the
treatment) from week 14 p.i till the end of the experiment.
IFN-γ is widely recognized as a major priming signal for macrophages’ activation, which have
a key role in effector phase of immune response to E. multilocularis. Macrophages provide for
the protoscoleces destruction by reactive oxygen metabolites production (superoxide anion,
hydrogenperoxide) [20]. The activation of peritoneal macrophages in the course of therapy was
evaluated by generation and release of superoxide anion (O2-). Although the most increase in
IFN-γ serum level in our experiment was found after GIZn therapy, GI had the strongest impact
on O2- release (Figure 17). Both GI+ABZ and GIZn+ABZ therapies resulted in the huge genera‐
tion of O2- from week 12 to 18 p.i., but with lower values in mice treated with GIZn+ABZ.
Figure 16. Serum IL-5 in E. multilocularis infected mice after immunotherapy with GI or GIZn. *(p<0.05); **(p<0.01) stat‐
istically significant from infected mice.
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A notable finding in the treatment efficacy was that GI’s presence in GI+ABZ therapy partly
inhibited the parasitostatic effect of ABZ (Figure 18).
It could be explained by GI’s stimulatory effect on fibrosis in periparasitic granuloma, which
could inhibit anthelmintic drug from penetrating to parasite vesicle. The glucan’s profibrotic
activity in metacestode infection Mesocestoides corti was found in [83], where glucan therapy
stimulated mononuclear-phagocytic cells in the liver followed by increased fibrotic process
around parasite’s larvae. In our experiment, GIZn+ABZ therapy was evaluated as the most
effective therapeutic approach to alveolar echinococcosis, because it stopped larval cyst’s
growth in the host till week 14 p.i. This coincides with the highest levels of IFN-γ in our
experiment – the cytokine with an antifibrotic property [21]. Cytokine IFN-γ plays a key role
in the regulation of collagen metabolism and might ameliorate liver fibrogenesis. Also in [84]
it was documented that IFN-γ downregulated lysyl oxidase gene expression, an essential
catalyst for the cross-linking of extracellular collagen and elastin.
In our experiment, the stimulation of IFN-γ production induced by GIZn could reduce the
irreversible fibrosis in periparasitic granuloma and thus allow penetration of anthelmintics to
larvocyst. IFN-γ has not only an antifibrotic property, but it is also engaged in Th1 immune
reactions, which are protective against E. multilocularis and include fibrogenesis. A correlation
of T cell immune response and hepatic fibrosis was found in [85]; serum IFN-γ levels were
negatively correlated with serological markers of fibrosis. Another immunological component
connected with fibrogenesis appear to be reactive oxygen metabolites produced by macro‐
phages. Superoxide anion, hydrogenperoxide, and hydroxyl radical are important stimuli to
colagen gene induction of hepatic stellate cells (HSC) [86]. Collagen synthesis and subsequent
cross-linking of collagen by pyridinoline, leading to irreversible fibrosis in periparasitic
granuloma, is a substantial component of the host immune reaction in forming a resistance
against parasite growth [87]. Therefore, the stimulation of fibrotic process could be beneficial
Figure 17. Macrophages’ activity in E. multilocularis infected mice after immunotherapy with GI or GIZn. *(p<0.05);
**(p<0.01) statistically significant from infected mice.
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for the host. On the contrary, overproduction of fibrous tissue may be harmful for host, as
fibrosis results in many complications of alveolar echinococcosis in patients: vasculary and
biliary obstructions in the liver [88]. In our experiment, the greatest inducer of O2- generation
in peritoneal macrophages (connected with hepatic fibrosis) was GI. On the other hand, GI
supplemented with zinc induced a short-time and a weaker production of this metabolite.
Zinc plays an important role as cofactor of enzymes involved in collagen synthesis [89] and
zinc supplemention has favorable inhibitive effects on hepatic fibrosis [90, 91]. This fact can
explain better the antiparasitic efficacy of treatment with GIZn and nearly twofold higher
efficacy of GIZn+ABZ therapy in comparison with ABZ treatment (Figure 18).
According to host’s immunosuppression and zinc deficiency in patients with alveolar echi‐
nococcosis [67], the combination of immunomodulator GIZn and anthelmintic drug ABZ
achieved the most effective control of the parasite infection. The parasitostatic effect of therapy
GIZn+ABZ lasted for the longest time; also after the end of the therapy it reached the greatest
reduction of E. multilocularis cysts in the host. Zinc supplemention of glucan immunomodu‐
lator improved its immunostimulatory effects on cellular immunity, which activated Th1
response and significantly stimulated IFN-γ cytokine synthesis. We suppose zinc positively
downregulated the liver fibrosis induced by glucan, because GIZn immunomodulator
suppressed the generation of superoxide – an activator of hepatic stella cells involved in the
fibrotic process.
7. Transfer factor
The dialysable leucocyte extract, a product of the immune system, is known as transfer factor
(TF). Transfer factors are low molecular weight dialysable products extracted from immune
Figure 18. Cyst’s weight in E. multilocularis infected mice after immunotherapy with GI or GIZn. *(p<0.05); **(p<0.01)
statistically significant from infected mice.
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cells which transmit the ability to express delayed-type hypersensitivity and cell-mediated
immunity from sensitized donors to nonimmune recipients [92]. TF increases macrophage
activation and IL-1, IL-2, and IFN-γ production in vitro and enhances leucocyte chemotaxis
and natural killer function [93, 94]. The TF preparates activated the proliferation of splenocytes
from animals with hypothyroidism [95] and stimulated hemopoiesis [96]. Transfer factor
stimulated antigen-specific cell-mediated response in patients with various infections, and so
administration of transfer factor has been recommended for patients with selective deficits in
cell-mediated immunity such as refractory neoplasms and chronic infections [94]. Adminis‐
tration of dialysable leucocyte extract has been shown to be free of hypersensitivity, long-
lasting side effects or complications, except for transitory hyperpyrexia.
Nonspecific transfer factor (TF) from the blood leukocytes of immunized swine was studied
as an appropriate candidate for immunotherapy, supplementing conventional ABZ treatment
of alveolar echinococcosis.
7.1. Experimental design
Experiments were carried out on male BALB/c mice (n=165) weighing 20–25 g. Mice were
randomly divided into five groups as follows:
Group 1 – uninfected and untreated (control)
Group 2 – infected intraperitoneally with 5000 E. multilocularis protoscoleces/mouse on Day 0
and no treatment
Group 3 – E. multilocularis infected (as Group 2) and treated with transfer factor (TF) (Imunor,
ImunomedicA, Czech Republic) per os (p.o.) twice a week at the dose of 200 μg/kg of body
weight (b.w.) starting at week 5 up to week 10 p.i.
Group 4 – E. multilocularis infected (as Group 2) and treated with albendazole (ABZ) (Sigma,
Germany) per os (p.o.) twice a week at the dose of 10 mg/kg of b.w. starting at week 5 up to
week 10 p.i.
Group 5 – E. multilocularis infected (as Group 2) and treated with combination of TF and ABZ
as above
Samples of blood, spleen, and peritoneal macrophages were obtained at the following weeks:
0 (prior infection), 2, 4, 6, 8, 10, 12, 14, 18, 22, and 26 p.i. from all groups (3 mice per experimental
day).
8. Results and discussion
Transfer factors (TFs) are proteins that transfer specific cellular immunity from an immune
donor to a nonimmune recipient and possess a number of nonspecific activities, such as the
ability to increase the numbers of immunocompetent cells, to stimulate phagocytosis, to induce
the production of interferons and interleukins, to stimulate hemopoiesis, etc. TF includes a lot
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of molecules, acting as antigens (MW cca 5 kDa), or acting as immunomodulators (less than
3.5 kDa) [97]. Transfer factors are very efficient in diseases in which cellular immunity plays
an important role in protection and control of the disease, for example, viral, bacterial, and
parasite infections, as well as immunodeficiencies and some types of cancer [98].
The host cellular immunity plays a principal role in the control of the E. multilocularis prolif‐
eration, which was documented by experiments, in which mouse strains not developing
cellular immune response do not control metacestode growth, while mice deficient in humoral
immunity control parasite growth up to a certain level [99]. Furthermore, T-cell immunity
significantly contributes to the control of alveolar echinococcosis in human patients, demon‐
strated by the rapid fatal outcome of the infection in an immunodeficient patient coinfected
with human immunodeficiency virus (HIV) [100]. Upon restoration of CD4-immunocomp‐
tence in another AIDS-patient coinfected with E. multilocularis, the course of disease was
positively influenced again [101].
In our work, both the therapy with TF or combination of TF+ABZ abolished a suppressory
impact of E. multilocularis infection on T- and B-cell proliferation (Figures 19, 20) and the
therapeutic stimulatory effect was recorded up to week 14 p.i., that is, one month after the end
of the therapy. Immunomodulating activity of TF on lymphocyte functional status was also
recorded by [95], who detected an increased proliferation of splenocytes from rats with
hypothyroidism induced by TF. A significant stimulative effect of TF on T- and B-cell popu‐
lations was also confirmed in experimental ascariasis in pigs [63].
Figure 19. Proliferative activity of T lymphocytes in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05);
**(p<0.01) statistically significant from infected mice.
T lymphocytes play a key role in the control of immune response in alveolar echinococcosis
[18, 36]. In our study, the administration of TF alone or in combination of TF+ABZ caused the
increase in numbers of CD4+ T cells in the spleen of infected mice up to week 14 p.i. (Figure
21). Patients with active alveolar echinococcosis showed increased numbers of CD8+ T
lymphocytes [20] and also our results documented an increase in this subpopulation after E.
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multilocularis infection from weeks 4 to 8 p.i., that is, during the massive proliferation of larval
cysts. The CD8+ T cells were not markedly influenced with TF immunomodulator, because all
therapeutic approaches inhibited the CD8+ T cell numbers during drug administration, from
weeks 6 to 10 p.i., but with no effect after the end of therapies. The splenic CD8+ T subpopu‐
lation in alveolar echinococcosis are mostly T suppressor cells [78]. Therefore, we deduce that
TF therapy stopped the development of host immunosuppression only for a short time, during
the drug administration. The increase in CD4+ T lymphocytes induced by TF was also observed
in viral infection (herpes zoster) and CD8+ T lymphocytes showed less decrease [102], similar
to our results.
Figure 20. Proliferative activity of B lymphocytes in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05);
**(p<0.01) statistically significant from infected mice.
Figure 21. Number of splenic CD4 T cells in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05) statistically
significant from infected mice.
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Active alveolar echinococcosis is related to Th2 response – dominance of IL-5 and IL-10 and
week production of IFN-γ [20]. The superiority of Th1 response plays a key role in the host
defence reactions against E. multilocularis. TF therapy selectively affects cytokine production
in response to antigen stimulation, particularly by secreting IFN-γ [93]. In our experiment, the
results of cytokine proteins detected by capture ELISA may not correlate with the levels of
bioactive cytokine protein. ELISA may utilize anticytokine antibodies that cannot discriminate
between the precursor (inactive) and mature (bioactive) forms of a cytokine protein. Moreover,
an ELISA may detect partially degraded cytokine proteins, which have retained their immu‐
noreactive properties but may have lost their bioactivity [103, 104]. But capture ELISA is a
helpful indicator of cytokine presence, although it does not reflect the biological potency of
the detected cytokines.
The concentration of serum IFN-γ in mice infected with E. multilocularis and treated with TF
or both TF+ABZ (Figure 22) was increased during therapy and also for one month after therapy
(from weeks 6 to 14 p.i.). The stimulative effect of TF on Th1 response, particularly together
with drug TF+ABZ, was observed in IFN-γ production in vitro [105], where high release of this
cytokine from splenocytes was found till the end of the experiment. Similar results were
achieved in mice with tuberculosis and treated with TF and antibiotics [98]. Th1-inducing effect
of TF was also confirmed in antitumour immunotherapy [92]. The concentration of IL-5 in
serum in mice infected with E. multilocularis and treated with TF or TF+ABZ in our work was
suppressed till the end of the experiment. This is consistent with an inhibited production of
IL-5 in vitro after immunotherapy with TF and TF+ABZ [105], which was significantly
decreased two weeks after the end of the therapy. The intensive Th2 downregulative effect of
TF was found by [93], who detected low splenocytes secretion of IL-10 and no IL-4. This
cytokine IL-5 modulates eosinophilia, IgE production, and can enhance allergic reactions of
the disease [20].
Figure 22. Serum IFN-γ in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05); **(p<0.01) statistically signifi‐
cant from infected mice.
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Figure 23. Macrophages’ activity in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05); **(p<0.01) statisti‐
cally significant from infected mice.
IFN-γ (that was stimulated after TF therapy) is an important activator of macrophages and
affects their energetic system [21]. Immunotherapy with TF or TF+ABZ activated the respira‐
tory burst in macrophages with high generation of O2- for a long time, from weeks 8 to 18 p.i.
(Figure 23). This is documented by a long-term stimulation of macrophages’ metabolic activity
accompanied with a high production of also other biologically effective substances. At the
same time, the proliferation of B cells and the IFN-γ level were increased. B cells release
stimulation factors for macrophages after activation with antigens from destroyed Echinococ‐
cus protoscoleces [46] and cytokine IFN-γ markedly affects the macrophage energetic system.
In our study, high concentrations of IFN-γ time-matched with intensive O2- production and
slow parasite proliferation in infected mice treated with TF or TF+ABZ. Stimulative effect of
TF on macrophages’ metabolism had also been recorded by [106], who found the TF dialysis
fraction (less than 3500 MW) activating the capacity of peritoneal macrophages to produce
superoxide anion.
Activation of effector components of immune response after the immunotherapy of E.
multilocularis infected mice in our experiment reduced the parasite growth and limited the
development of larval cysts in the host (Figure 24). The immunomodulatory effect of TF
suppressed the parasite proliferation till week 14 p.i. with the similar activity to anthelmintic
drug albendazole and prolonged the parasite-reducing effect for one month, that is, till week
18 p.i. The TF-inhibiting effect on the parasite development was associated with the time of
TF administration and a short time after it. The addition of TF to albendazole therapy resulted
in a high antiparasitic effect with a significant cyst’s reduction up to week 18 p.i. (2 months
after the end of the therapy) in comparison to untreated group. Thereafter, the protective effect
of anthelmintic therapy was lost.
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Figure 24. Cyst’s weight in E. multilocularis infected mice after therapy TF+ABZ. *(p<0.05); **(p<0.01) statistically signif‐
icant from infected mice.
In conclusion, the results of our study suggest that TF can have a positive effect on the host
cellular immune response against the development of E. multilocularis. Nowadays, it is known
that TF consists of a high quantity of low molecular weight proteins (> 200), and the exact
chemical nature and molecular mechanisms of its action have not been defined yet. Low
synthesis of IFN-γ induced by the E. multilocularis infection was restored with TF and exceeded
the control concentration. The rise recorded in IFN-γ cytokine could be explained as a result
of immunorestoration of CD4+ Th1 lymphocytes or due to the proliferation of another CD4
subpopulation. We think that regulation of immune homeostasis with TF therapy, which
occurred between the CD4 cells and IFN-γ, played an important role in the immune response
to E. multilocularis infection. Regulatory and effector mechanisms (CD4+ T cells, IFN-γ, and
macrophages) which actively participate in the parasite destruction were stimulated with TF
and supported antiparasitic effect of albendazole.
9. Conclusion
Our results suggest the possible way to increase ABZ antiparasitic efficacy in E. multilocula‐
ris infection by stimulation of the host immune response.
L-MTP-PE was recognized as a strong macrophage activator in mice infected with E. multilo‐
cularis. This immunomodulator stimulated the superoxide anion production for 3 months. The
activity of macrophages was supported by dominant Th1 protective response – considered the
highest serum IFN-γ level in that time. The antiparasitic effect of combined L-MTP-PE +ABZ
therapy was manifested by marked reduction of cysts growth for 3 months after the end of
treatment.
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GIZn+ABZ has been shown to be the most effective immunomodulatory and antiparasitic
treatment, the greatest reduction of metacestode growth was observed as early as 2 weeks from
the beginning of this therapy, lasting till the end of experiment (for 4 months). The addition
of zinc to immunomodulatory glucan substance has greatly contributed to the reduction of
intensive fibrosis after glucan treatment, which attenuated the antiparasitic effect of ABZ alone.
TF could correct the immune balance disturbance after the E. multilocularis infection, which is
responsible for lymphocyte suppressor activity. Inhibited IFN-γ production after the E.
multilocularis infection was restored and increased with TF, which could result from a resto‐
ration of CD4+ Th1 lymphocytes. TF administration prolonged the parasitostatic effect of ABZ
for 2 months. Restoration of suppressed host immune mechanisms that are important for
restriction of parasite expansive growth seems to be a promissing approach to E. multilocula‐
ris infection.
Immunomodulatory agents can be beneficial in the treatment of alveolar echinococcosis, where
the developed Th1 immune response supports the improvement of the anthelmintic action of
benzimidazoles. The type and development of the immune response are generally managed
by the lymphocyte network and its immunoregulatory mechanism. Immunomodulators could
regulate the immune disbalance after the E. multilocularis infection, which suppresses lym‐
phocytes’ and macrophages’ activities. Restoring of this immunosuppresion may be one
promising way to overcome this situation and to control chronic alveolar echinococcosis.
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